NCT02198508.

Methods	Randomised, open‐label, single‐centre, cross‐over study.
Participants	Target sample size: 13 Inclusion criteria 18 years of age or older Serum ferritin greater than 2000 ng/mL Serum creatinine within normal range for a measuring laboratory Platelet count exceeding 140000/mm³ Body weight at least 40 kg None had a history of clinical significant of gastrointestinal, hepatic, renal, endocrine, oncologic, infectious, pulmonary or cardiovascular disease Exclusion criteria HIV positive, history of immunologic hypersensitivity to any medication Women pregnant or breastfeeding Drug or alcohol abuse Patients showed abnormal or irregular bowel function (defined as more than three bowel movements a day or less than one bowel movement every other day) Receiving warfarin, digoxin, or anti‐arrhythmic or anti‐seizure medication
Interventions	Experimental: combination treatment: DFX and DFP Active comparator: DFX Active comparator: DFP
Outcomes	Primary outcome: Iron excretion from urine and faeces by flame atomic absorption spectroscopy [time frame: 25 days] Secondary outcome: Drug concentration in plasma by pharmacokinetics analysis [time frame: 25 days]
Notes	Primary completion date: July 2008 Recruitment status: completed Author was contacted

AE: adverse event
 AUC: area under the curve
 Cmax: maximum or peak concentration (of a drug observed after its administration)
 Cmin: minimum concentration (of a drug observed after its administration)
 DFO: deferoxamine
 DFP: deferiprone
 DFX: deferasirox
 EU: European Union
 GFR: glomerular filtration rate
 GIQLI: Gastrointestinal Quality of Life Index
 GI: gastrointestinal
 GSRS: Gastrointestinal Symptom Rating Scale
 LIC: liver iron concentration
 LVEF: left ventricular ejection fraction
 MRI: magnetic resonance imaging
 SD: standard deviation
 SGPT: serum glutamic‐pyruvic transaminase
 TIBC: total iron building capacity